Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.

As the Trump administration begins to make its mark on the Medicare drug price negotiation program, litigation over the ...

SIGNIFICANT EVENTS DURING 1 APRIL - 30 JUNE 2025In April, Iconovo announced an organizational change expected to reduce annual costs by approximately 14-16 MSEK starting in the third quarter of 2025.

New guidelines offer actionable recommendations for diagnosing and managing asthma, making it easier for primary care ...

AstraZeneca is currently conducting a clinical study titled A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials.

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar ...

AstraZeneca has launched a Phase IIb clinical study titled ‘A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in ...

(Reuters) -AstraZeneca’s experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and challenges shaping SMMT's future.

AstraZeneca's potential shift to the US highlights challenges for Reeves and the UK biopharmaceutical sector.